Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myeloid, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia 3Immunoblastic Lymphadenopathy 3Myelodysplastic Syndromes 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Large Granular Lymphocytic 2Hematologic Neoplasms 2Enteropathy-Associated T-Cell Lymphoma 2Waldenstrom Macroglobulinemia 1Sezary Syndrome 1Recurrence 1Mycosis Fungoides 1Mastocytosis, Systemic 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphatic Diseases 1Leukemia, Mast-Cell 1Leukemia, Hairy Cell 1

Interventions

midostaurin 3avapritinib 2ripretinib 1obatoclax 1nilotinib 1ibrutinib 1dexamethasone acetate 1dexamethasone 21-phosphate 1denileukin diftitox 1auricularum 1Ranitidine 1Interviews as Topic 1Imatinib Mesylate 1Ibuprofen 1Diphenhydramine 1Dexamethasone 1Calcium Dobesilate 1Brentuximab Vedotin 1Azacitidine 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mastocytosis, Systemic × Brentuximab Vedotin × Other hematologic neoplasm × Clear all
NCT01807598 2019-01-29

Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia

Stanford University

Phase 2 Completed
10 enrolled 14 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡